Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: Volcano888 who wrote (132)	12/10/1997 9:16:00 AM
From: F. Jay Abella, III	Read Replies (1) \| Respond to of 523

Published today at westergaard.com ...Protein Design Labs (Nsdq:PDLI), and Neurogen (Nsdq: NRGN). For PDLI, its drop 7.375 points to 39.375 was in reaction to news that its development partner, Boehringer Mannheim GmbH had exited its hepatitis and CMV retinitis collaborations. Dropping a CMV retinitis drug, to us is a positive for PDLI, after seeing that GILD's Vistide for the same disease has only realized about $15mm in total sales since mid 1996. As for Neurogen, its shares fell on Tuesday after the company said patients in an early-stage test of its obesity drug NGD 95-1 experienced unexpected, but "significant (severe?) elevation of certain liver enzymes." This news resulted in a loss of $96.5mm of market cap for NRGN, 1/3 its former value. We see this as yet another example of why SuperGen (Nsdq:SUPG) is the model of downside risk management in biotech. From investor reaction to the NRGN news, we see that the present contribution to market cap of early stage obesity drugs is $100mm. We ask if investors have built $100mm of value into the shares of SuperGen for their obesity drug, now in Phase II trials? If so, that only leaves $180mm in value for its entire generics line, supergenerics, and proprietary compounds - products from which the company has been put on all the major HMO formularies and will garner profitability by end 1998. $180mm for a profitable company in biotech? No such thing. Comments?